China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma
|
By IntellAsia: Resources
on 7/21/2021
--Phase III trial will evaluate progression-free survival and overall survival of patients with recurrent glioblastoma --Glioblastoma has an incidence rate of approximately 2.85 to 4.56 per 100,000 population ...
Full "IntellAsia: Resources" article
|
|